After several trials with neutral outcomes, renal denervation had been demoted for some time. However, this new study presented at EuroPCR 2018 and simultaneously published in the LANCET brings back the technique with improved devices that seem to yield improved outcomes. The study included patients with uncontrolled arterial hypertension under medical treatment. Eligible patients<a href="https://solaci.org/en/2018/05/29/europcr-2018-spyral-htn-on-med-renal-denervation-comes-back-to-life/" title="Read more" >...</a>
EuroPCR 2018 | Meta-Analyzis on Cerebral Protection Devices during TAVR
The risk of stroke is inherent to TAVR and, apart from clinically manifest events, there is abundant evidence of cerebral embolic lesions during TAVR provided by studies using diffusion weighted MRI or transcranial doppler ultrasound. Several devices have been developed to reduce the risk of stroke, though they have been assessed by relatively small trials<a href="https://solaci.org/en/2018/05/29/europcr-2018-meta-analyzis-on-cerebral-protection-devices-during-tavr/" title="Read more" >...</a>
Is TAVR Durable Beyond 5 Years?
Courtesy of Dr. Carlos Fava. The benefits derived from transcatheter aortic valve replacement (TAVR) are clear and self-evident, and its progressively better outcomes are due to better patient selection, greater operator experience, and the development of new valves that enhance procedural safety and complexity. However, the question of durability remains a major unresolved issue, particularly now<a href="https://solaci.org/en/2018/05/22/is-tavr-durable-beyond-5-years/" title="Read more" >...</a>
See the Scientific Program of the Guatemala Sessions 2018
SOLACI returns to Guatemala after a decade, in order to continue boosting the development of interventional cardiovascular medicine in Latin America. With that in mind, the scientific program developed for these Sessions is appealing and includes valuable oral presentations on interesting topics such as structural heart disease, acute coronary syndromes, coronary diseases, and valve heart<a href="https://solaci.org/en/2018/05/08/see-the-scientific-program-of-the-guatemala-sessions-2018/" title="Read more" >...</a>
All you need to know about Guatemala Sessions 2018
After over ten years, SOLACI returns to the country that hosted the first Regional Sessions: Guatemala. After such a long time, it will be our honor to return there in our mission to continue promoting interventional cardiology through an event that consists in an array of the most varied scientific sessions and activities. Are you planning<a href="https://solaci.org/en/2018/05/07/all-you-need-to-know-about-guatemala-sessions-2018/" title="Read more" >...</a>
Baseline Pulmonary Hypertension Should Not Preclude TAVR
Pulmonary hypertension (PH) in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement (TAVR) should not preclude this procedure. In fact, TAVR will resolve this condition in most cases. More than three quarters of patients undergoing TAVR have some level of PH, though this has not been associated to increased mortality, according to this<a href="https://solaci.org/en/2018/05/04/baseline-pulmonary-hypertension-should-not-preclude-tavr/" title="Read more" >...</a>
Liver Failure as a Challenge for TAVR
Although surgical risk scores do not include liver failure (LF), patients who suffer from it and undergo cardiovascular surgery present high rates of morbidity and mortality. This is due to alteration of cardiac function, increased infection susceptibility, gastrointestinal complications, and increased bleeding. As regards transcatheter aortic valve replacement (TAVR), these patients have not been included<a href="https://solaci.org/en/2018/05/03/liver-failure-as-a-challenge-for-tavr/" title="Read more" >...</a>
TAVR with Prior MRS: A New Challenge
The benefits of transcatheter aortic valve replacement (TAVR) for high-risk, prohibitive-risk (class I) or intermediate-risk (class IIa) patients have already been proven, but there is a growing population of patients with a history of myocardial revascularization surgery (MRS) who experience severe aortic stenosis. Decision-making in these cases is anything but simple, mainly due to the presence of<a href="https://solaci.org/en/2018/05/02/tavr-with-prior-mrs-a-new-challenge/" title="Read more" >...</a>
Constrictive Pericarditis After Pericardiocentesis
All interventional cardiologists must be able to perform a pericardiocentesis. Whether we deal with a chronic total occlusion, a supposedly simple coronary angioplasty (we all have witnessed the perforation of a supposedly risk-free coronary artery), or a transcatheter aortic valve replacement (whose rise gave us another significant source of tamponades), we must all be ready<a href="https://solaci.org/en/2018/04/25/constrictive-pericarditis-after-pericardiocentesis/" title="Read more" >...</a>
We Should Consider Mitral Stenosis Before TAVR
The association between aortic stenosis and some degree of mitral stenosis (MS) is around 10% (depending on the series), and it is related with negative outcomes. In high-risk and inoperable patients who underwent TAVR, that association and its significance have not been studied yet. The study analyzed data from the Society of Thoracic Surgeons/American<a href="https://solaci.org/en/2018/04/21/we-should-consider-mitral-stenosis-before-tavr/" title="Read more" >...</a>